Becton Dickinson Q4 FY2026 Results: Net Income $696 Million on Revenue of $5.27 Billion
- US stocks
- Earnings
- Health Care

Becton Dickinson (NYSE: BDX) reported GAAP revenue of $5.27 billion and GAAP net income of $696.0 million for the fiscal 2026 fourth quarter, the three months to 30 Sep 2026, and it said on 5 Nov 2026. GAAP diluted EPS was $2.54, and the company's adjusted diluted EPS, a company-defined measure that excludes items such as purchase accounting adjustments and restructuring costs, was $4.15.
Key highlights
- Revenue (GAAP): $5.27 billion, up 5.4% YoY
- Operating income (GAAP): $1.03 billion, up 92.5% YoY
- Net income (GAAP): $696.0 million, up 41.2% YoY
- Diluted EPS (GAAP): $2.54, up 47.7% YoY
- Adjusted diluted EPS (company-defined): $4.15, up 27.3% YoY
Summary
| Particulars | Q4 FY2026 | Q4 FY2025 | YoY |
|---|---|---|---|
| Revenue | 5,274.0 | 5,005.0 | +5.4% |
| 1,032.0 | 536.0 | +92.5% | |
| Operating margin | 19.57% | 10.71% | +8.86 pp |
| 696.0 | 493.0 | +41.2% | |
| Net income margin | 13.20% | 9.85% | +3.35 pp |
| Diluted EPS ($) | 2.54 | 1.72 | +47.7% |
Figures are in $ million except EPS; YoY compares with Q4 FY2025. Q4 FY2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are the release's own comparatives, not cross-checked against SEC XBRL data. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows GAAP revenue up 5.4% from a year earlier, and GAAP operating margin of 19.6% against 10.7% a year earlier. The release says prior periods have been recast to conform to its continuing operations basis.
Net income was 13.2% of revenue this quarter, against 9.9% a year earlier (3.3 percentage points higher).
Adjusted figures exclude tariff refunds and legal charges
Adjusted diluted EPS is the company's own non-GAAP measure. It excludes items the release names, including purchase accounting adjustments, integration and restructuring costs, and separation-related items. For the fourth quarter, the company said the adjustments included a benefit of $66 million, mainly to cost of products sold, from refunds of tariffs imposed under IEEPA, and net charges of $45 million to other operating expense for product liability and certain other legal matters.
Interventional revenue rose 7.6% in the quarter
Interventional revenue was $1.47 billion, up 7.6%. Medical Essentials revenue was $1.79 billion, up 5.9%, and BioPharma Systems revenue was $748.0 million, up 6.5%.
United States revenue was $3.20 billion, up 4.3%, and International revenue was $2.07 billion, up 7.0% as reported and 7.6% on a foreign currency neutral basis.
Fiscal 2027 adjusted EPS outlook is $13.10 to $13.30
The company expects fiscal 2027 adjusted diluted EPS of $13.10 to $13.30 and low single-digit GAAP revenue growth, with revenue growth on a foreign currency neutral basis also at a low single-digit rate. The release gives no prior range for these figures.
For fiscal 2026, free cash flow, a company-defined non-GAAP measure, was $2.93 billion, up 42.5%, and cash from continuing operating activities was $3.60 billion, up 30.0%.
Inference
Diluted average shares outstanding fell from 287,118 thousand a year earlier to 274,051 thousand in the quarter. In fiscal 2026 the company repurchased $2.43 billion of common stock and paid $1.16 billion in dividends.
The release does not state a dividend declared for the period, and it gives no fiscal 2027 GAAP EPS outlook. The next dated step it names is the 2026 Investor Day on 10 Dec at the New York Stock Exchange.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

